poisar

Stocks · News reference

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

BenzingaVandana Singh

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading